IMTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Immatics NV (IMTX) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the technical indicators show some bullish trends, the lack of significant positive news, weak financial performance, and neutral sentiment from hedge funds and insiders suggest a cautious approach. The stock's recent price trend and lack of strong trading signals also do not provide a compelling entry point.
The MACD is slightly positive at 0.0418, indicating mild bullish momentum, but it is contracting. RSI is neutral at 53.256, showing no clear overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading near its pivot level of 10.061, with resistance at 10.393 and support at 9.729. Overall, the technicals suggest mild bullishness but no strong breakout signals.
and a bullish outlook on the biotech sector. Gross margin remains strong at 100%.
Revenue dropped significantly by -89.74% YoY in Q3 2025, and net income remains negative at -$50.54M despite improvement. No recent news or significant insider/hedge fund activity. Congress trading data is absent. Stock trend analysis indicates a likelihood of minor declines in the short term.
In Q3 2025, revenue dropped sharply by -89.74% YoY to $5.19M. However, net income improved significantly YoY to -$50.54M (up 489.79%), and EPS increased to -0.42 (up 425%). Gross margin remained strong at 100%, but the overall financial performance reflects weak growth trends.
Analysts are positive on the stock, with Mizuho raising the price target to $25 and BofA to $17, maintaining Outperform and Buy ratings, respectively. Analysts highlight positive data catalysts and improving biotech sector conditions, but concerns about sustainability remain.
